Assessing walking function in children with juvenile idiopathic arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the Dynamic Gait Index (DGI) as a functional assessment tool for walking in children diagnosed with juvenile idiopathic arthritis (JIA). The DGI measures various aspects of walking, including speed changes, head turns, and obstacle navigation, to identify gait disorders that may arise from JIA. The study includes children aged 8-16 with unilateral knee involvement and compares their results to a control group without any neurological or orthopedic conditions. By establishing the DGI's effectiveness in this population, the study aims to enhance the understanding of walking difficulties in children with JIA.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Study Group;
* Having a JIA diagnosis according to ILAR criteria between the ages of 8-16,
* Having unilateral knee joint involvement that will affect walking
* Being compatible, volunteer and cooperative in the study Control Group;

  1. Not having any neurological or orthopedic diagnosis
  2. Being between the ages of 8-16
  3. Being at a mental level that can understand the commands of the person performing the evaluation

Exclusion Criteria:

* Study Group;
* Having an additional neurological or orthopedic diagnosis accompanying JIA and affecting treatment results,
* Having lower extremity asymmetry or active lower extremity involvement other than the knee joint that will affect walking.

Control Group;

-Having any health problem that may affect the study

Where it's running

• Istanbul University-Cerrahpasa
  Istanbul, Turkey, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Gökçe Leblebici, PhD
• Email: leblebicigokce@gmail.com
• Phone: +905397395718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using infrared cameras to help detect juvenile arthritis in kids

  This study tests whether infrared thermography can help identify joint inflammation in children with juvenile idiopathic arthritis compared with standard tests.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens · NCT07914179

• Oral health, saliva bacteria, and disease activity in children with JIA

  This study checks if how active juvenile idiopathic arthritis is relates to oral health in children who already receive rheumatology care.

  Recruiting Shanghai Jiao Tong University School of Medicine · Shanghai, Pudongxinqu · NCT07799831

• Olokizumab treatment for children with polyarticular juvenile idiopathic arthritis

  This test gives weight-based doses of olokizumab every 4 weeks to see if it helps control polyarticular juvenile idiopathic arthritis and is safe for children aged 2–17.

  Recruiting at 14 sites Phase 2 R-Pharm · Kazan' and 13 other locations · NCT07517575

• Post-marketing surveillance of Cosentyx (secukinumab) for hidradenitis suppurativa, pediatric plaque psoriasis, and juvenile idiopathic arthritis in Korea

  This study will see how Cosentyx (secukinumab) works and is tolerated in people in Korea with moderate-to-severe hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis who are being treated in routine care.

  Recruiting Novartis · Seoul, Seoul · NCT07243782

• Understanding pain in juvenile idiopathic arthritis

  This project will test whether temperature and pressure pain tests, questionnaires, and blood or saliva samples can help explain pain in kids and teens (ages 9–17) with juvenile idiopathic arthritis.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07217782

• Follow-up care for new cases of polyarthritis in children and young adults

  This program will try standardized medical follow-up for children and young adults (≤50) with new-onset JIA, RA, psoriatic/seronegative/undifferentiated arthritis, SLE, or diffuse systemic sclerosis who are treatment-naïve or treated ≤3 months to see if more patients reach disease control or remission.

  Recruiting Université Catholique de Louvain · Brussels · NCT07000916

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.